Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321550 | 1.00 | THRA (0.31) | THRATHRBHSD11B1 | |
| SCHEMBL27557074 | 0.84 | — | — | |
| SCHEMBL527479 | 0.83 | DPP4 (0.30) | — | |
| SCHEMBL31708245 | 0.83 | EPHX1 (0.31) | — | |
| SCHEMBL482043 | 0.82 | NR1H2 (0.33) | — | |
| SCHEMBL343055 | 0.82 | NR1H2 (0.33) | — | |
| SCHEMBL482044 | 0.82 | NR1H2 (0.33) | — | |
| SCHEMBL16525254 | 0.82 | — | — | |
| SCHEMBL16525252 | 0.82 | — | — | |
| SCHEMBL23826916 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102947310-B | Fused pyridine compounds as dual modulators of the 5-HT2A and D3 receptors | HOFFMAN-LA ROCHE LTD. (CH) | 2015-11-25 | — | — | CN | disclosed |
| EP-2675798-B1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | disclosed |
| EP-2590984-B1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2015-01-28 | — | — | EP | disclosed |
| US-8921397-B2 | Benzofurane-piperidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8877778-B2 | Benzofurane compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2582705-B1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8722683-B2 | Benzodioxole piperazine compounds | HOFFMANN LA-ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2704707-A1 | NOVEL BENZOFURANE-PIPERIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2680840-A1 | NOVEL BENZODIOXOLE PIPERIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2675798-A1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012110470-A1 | NOVEL BENZODIOXOLE PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-23 | — | — | WO | disclosed |
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012080149-A1 | NOVEL BENZOFURANE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012004206-A1 | ANELLATED PYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| EP-1824483-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050239-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157449-A1 | BENZOFURANE COMPOUNDS | HTR3A, HTR3C, HTR2A | THRA 520/4885THRB 492/4885HSD11B1 1297/4885 |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | THRA 277/4885THRB 180/4885HSD11B1 3554/4885 |
| US-20120010201-A1 | NOVEL ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | THRA 412/4885THRB 658/4885HSD11B1 1599/4885 |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | THRA 498/4885THRB 795/4885HSD11B1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.